United States Biotechnology & Medical Research

Alto Neuroscience Inc (ANRO)

Alto Neuroscience Inc. experienced significant insider selling recently, with President and CFO Nicholas Smith executing four planned transactions totaling approximately $7.16 million in late September. These divestments follow an 11.1% decline in stock value over the past quarter, occurring after the company's August earnings report showed an 8.45% earnings per share beat.
Ticker: ANRO Exchange: NYS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Alto Neuroscience Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
1.3
Smith Nicholas Conrad PRESIDENT AND CFO Officer
Transaction date
Planned sale
Price
179.85
Quantity 21,627 +18.6%
Value US$3,254,393
1.3
Smith Nicholas Conrad PRESIDENT AND CFO Officer
Transaction date
Planned sale
Price
88.22
Quantity 4,785 -13.4%
Value US$4,982,893
1.3
Smith Nicholas Conrad PRESIDENT AND CFO Officer
Transaction date
Planned sale
Price
29.86
Quantity 25,125 +42.3%
Value US$4,155,374
1.3
NICHOLAS SMITH Officer Officer
Transaction date
Proposed sale
Price
26.66
Quantity 134,886
Value US$3,596,061
0.9
Savitz Adam CHIEF MEDICAL OFFICER Officer
Transaction date
Purchase
Price
13.22
Quantity 2,931 +7.9%
Value US$38,748
0.9
Savitz Adam CHIEF MEDICAL OFFICER Officer
Transaction date
Purchase
Price
13.15
Quantity 1,388 +3.9%
Value US$18,252
0.9
Savitz Adam CHIEF MEDICAL OFFICER Officer
Transaction date
Purchase
Price
12.53
Quantity 10,681 +43.0%
Value US$133,833
1.3
Smith Nicholas Conrad CHIEF FINANCIAL OFFICER Officer
Transaction date
Purchase
Price
16.56
Quantity 4,550 +20.4%
Value US$75,348
1.3
Smith Nicholas Conrad CHIEF FINANCIAL OFFICER Officer
Transaction date
Purchase
Price
15.80
Quantity 1,600 +7.7%
Value US$25,280
Alpha Wave Global, LP Large shareholder
Transaction date
Purchase
Price
16.00
Quantity 600,000 +19.3%
Value US$9,600,000
1.3
Smith Nicholas Conrad CHIEF FINANCIAL OFFICER Officer
Transaction date
Purchase
Price
16.00
Quantity 1,563 New position
Value US$25,008
0.9
Savitz Adam CHIEF MEDICAL OFFICER Officer
Transaction date
Purchase
Price
16.00
Quantity 17,000 +216.5%
Value US$272,000
Etkin Amit PRESIDENT AND CEO Executive Director
Transaction date
Purchase
Price
16.00
Quantity 3,125 +0.3%
Value US$50,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-10-01 2026-09-30 PlS Planned sale
1.3
Smith Nicholas Conrad

PRESIDENT AND CFO

Officer
21,627 +18.6%
179.85
US$3,254,393 		21,627 +18.6% 179.85 US$3,254,393
2026-10-01 2026-09-30 PlS Planned sale
1.3
Smith Nicholas Conrad

PRESIDENT AND CFO

Officer
4,785 -13.4%
88.22
US$4,982,893 		4,785 -13.4% 88.22 US$4,982,893
2026-10-01 2026-09-29 PlS Planned sale
1.3
Smith Nicholas Conrad

PRESIDENT AND CFO

Officer
25,125 +42.3%
29.86
US$4,155,374 		25,125 +42.3% 29.86 US$4,155,374
2026-09-29 2026-09-29 PrS Proposed sale
1.3
NICHOLAS SMITH

Officer

Officer
134,886
26.66
US$3,596,061 		134,886 26.66 US$3,596,061
2024-07-11 2024-07-10 B Purchase
0.9
Savitz Adam

CHIEF MEDICAL OFFICER

Officer
2,931 +7.9%
13.22
US$38,748 		2,931 +7.9% 13.22 US$38,748
2024-07-11 2024-07-09 B Purchase
0.9
Savitz Adam

CHIEF MEDICAL OFFICER

Officer
1,388 +3.9%
13.15
US$18,252 		1,388 +3.9% 13.15 US$18,252
2024-07-11 2024-07-09 B Purchase
0.9
Savitz Adam

CHIEF MEDICAL OFFICER

Officer
10,681 +43.0%
12.53
US$133,833 		10,681 +43.0% 12.53 US$133,833
2024-04-01 2024-03-28 B Purchase
1.3
Smith Nicholas Conrad

CHIEF FINANCIAL OFFICER

Officer
4,550 +20.4%
16.56
US$75,348 		4,550 +20.4% 16.56 US$75,348
2024-04-01 2024-03-28 B Purchase
1.3
Smith Nicholas Conrad

CHIEF FINANCIAL OFFICER

Officer
1,600 +7.7%
15.80
US$25,280 		1,600 +7.7% 15.80 US$25,280
2024-02-08 2024-02-06 B Purchase
Alpha Wave Global, LP
Large shareholder
600,000 +19.3%
16.00
US$9,600,000 		600,000 +19.3% 16.00 US$9,600,000
2024-02-07 2024-02-06 B Purchase
1.3
Smith Nicholas Conrad

CHIEF FINANCIAL OFFICER

Officer
1,563 New position
16.00
US$25,008 		1,563 New position 16.00 US$25,008
2024-02-07 2024-02-06 B Purchase
0.9
Savitz Adam

CHIEF MEDICAL OFFICER

Officer
17,000 +216.5%
16.00
US$272,000 		17,000 +216.5% 16.00 US$272,000
2024-02-07 2024-02-06 B Purchase
Etkin Amit

PRESIDENT AND CEO

Executive Director
3,125 +0.3%
16.00
US$50,000 		3,125 +0.3% 16.00 US$50,000
Explore more

More insider trading research around Alto Neuroscience Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America